AstraZeneca Enters Exclusive License Deal for Lung Cancer Drug Zegfrovy for Up to $1.5 Billion
(feeds.content.dowjones.io)
1.
2.
AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion
(feeds.content.dowjones.io)